Observational study in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Lourdes PoyatosDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.ORCID 0000-0002-4641-8600
Melani Núñez-MonteroDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.
Olga HladunDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.ORCID 0000-0002-6230-5876
Georgina De la RosaDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.
Soraya MartínDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.ORCID 0009-0008-3761-9217
Sebastian VidelaDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.
Silvia Martínez-CouseloDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.
Mireia VenturaEnergy Control, Associació Benestar i Desenvolupament, Carrer de la Independència 384, 08041 Barcelona, Spain.ORCID 0000-0003-1133-6872
Nunzia La MaidaNational Center On Addiction and Doping, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.ORCID 0000-0003-0127-4225
Annagiulia Di TranaNational Center On Addiction and Doping, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.ORCID 0000-0002-8456-0827
Francesco Paolo BusardòDepartment of Excellence-Biomedical Sciences and Public Health, Università Politecnica delle Marche, 60121 Ancona, Italy.
Marta TorrensDrug Addiction Unit, Parc de Salut Mar, Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Simona PichiniNational Center On Addiction and Doping, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.
Clara Pérez-MañáDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.ORCID 0000-0001-6343-6918
Magí FarréDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.ORCID 0000-0001-8338-7543
Esther PapaseitDepartment of Clinical Pharmacology and Biochemistry, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Carretera de Canyet S/N, 08916 Badalona, Spain.
Funding
Anti-drug Policies Department of the Italian Government No numberInstituto de Salud Carlos III PI17/01962, PI20/00879,PI24/00834,FI18/00179, PT20/00018, RD24/0003/0001, RD24/0003/0019
6 · The paper itself
Abstract
Synthetic cathinones represent the second most frequently reported group of new psychoactive substances identified annually, according to the United Nations. It remains unknown whether specific derivatives differ in the onset of effects related to absorption kinetics. Clephedrone (4-chloromethcathinone, 4-CMC) has been among the most frequently seized cathinones in recent years; however, available data on its pharmacology and abuse potential remain scarce. A non-controlled, prospective, observational study was conducted involving eight healthy volunteers (six women) who self-administered a single oral dose of clephedrone (100 or 150 mg). Study variables were assessed at baseline and over a 5-h period following administration, including vital signs and subjective effects. Oral fluid concentrations of clephedrone and cortisol were determined. For comparison, this article also presents previously unpublished data from a pilot study in which 12 healthy male participants received 150 or 200 mg of methylone under comparable conditions to evaluate effects. Results indicated that both clephedrone and methylone produced stimulant-like subjective effects. However, clephedrone exhibited a delayed onset and peak of effects compared with methylone, indicating a clinically relevant pharmacokinetic difference. Both substances were detected in oral fluid, with peak concentrations occurring later following clephedrone administration, consistent with its delayed pharmacodynamic profile.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Oral Fluid Concentrations and Pharmacological Effects of Clephedrone and Methylone in Humans. · full record | Socratic